Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Crestor 40 mg film-coated tablets
Medicines register · Ireland

Crestor 40 mg film-coated tablets

Authorisation PPA0465/441/004 · PCO Manufacturing Ltd.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
PCO Manufacturing Ltd. (all products →)
Active substance
Rosuvastatin
Clinical trials
40 clinical trials →
Dosage form
Film-coated tablet
Route of administration
Oral use
ATC codes
C10AA, C10AA07
First authorised
12/10/2018
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC

Rosuvastatin: supply and approvals

59 authorised products on the HPRA list contain Rosuvastatin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Parallel import (PPA). A parallel product authorisation: the HPRA allows this product to be imported from another EU or EEA country and sold in Ireland. It has been authorised for 8 years (since 12 October 2018). The HPRA list does not say whether it is on sale.

Other medicines with Rosuvastatin in Ireland

54 other products on the HPRA list contain Rosuvastatin, from 13 licence holders; 35 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Crestor 10 mg film-coated tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Crestor 20 mg film-coated tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Crestor 40 mg film-coated tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Crestor 5 mg film-coated tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Rosuva 10 mg film-coated tabletsRowex Limited,National authorisation (PA)Marketed
Rosuva 20 mg film-coated tabletsRowex Limited,National authorisation (PA)Marketed
Rosuva 40 mg film-coated tabletsRowex Limited,National authorisation (PA)Marketed
Rosuva 5 mg film-coated tabletsRowex Limited,National authorisation (PA)Marketed
Rosuvastatin Clonmel 10mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Rosuvastatin Clonmel 20mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Rosuvastatin Clonmel 40mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Rosuvastatin Clonmel 5mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed

All 55 products with Rosuvastatin →

Other substances in ATC group C10AA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 6 other active substances share the group C10AA with this product:

Atorvastatin (43) · Simvastatin (25) · Pravastatin sodium (12) · Atorvastatin calcium trihydrate (9) · Pitavastatin (3) · Fluvastatin sodium (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

PCO Manufacturing Ltd. holds 288 products on the HPRA list, with 164 different active substances; 1 of the products is marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.